Literature DB >> 29503056

Comparing Western and Eastern criteria for sarcopenia and their association with survival in patients with pancreatic cancer.

Chih-Horng Wu1, Ming-Chu Chang2, Vladimir K Lyadov3, Po-Chin Liang4, Chyi-Mong Chen4, Tiffany Ting-Fang Shih4, Yu-Ting Chang5.   

Abstract

BACKGROUND & AIMS: Sarcopenia and cachexia are associated with pancreatic cancer and serve as important adverse prognostic factors. Body composition can be analyzed by routine computed tomography (CT) for cancer staging and has been used to study many types of cancer. The CT measurements are robust, but the diagnostic criteria for sarcopenia vary among different studies. Age, sex and race are important factors that affect muscle and fat masses. This study aimed to analyze the effect of different sarcopenia diagnostic criteria on the prognosis of patients with pancreatic cancer.
METHODS: Patients with newly diagnosed pancreatic cancer at National Taiwan University Hospital between October 2013 and October 2016 were retrospectively reviewed in this study. Body composition was assessed using cross-sectional CT images to calculate the total skeletal muscle (TSM) index. The concordance and interobserver variability of the TSM measurements were evaluated using both the Western criteria and the Eastern criteria. Kaplan-Meier analyses and the Cox proportional hazard ratio with two different diagnostic criteria for sarcopenia were used to compare the effect on overall survival (OS).
RESULTS: A total of 146 patients with pancreatic cancer were enrolled. The TSM index measured by the Western institute was highly correlated with that measured by the Eastern institute (r = 0.953, p < 0.001). The prevalence of sarcopenia in the patient group at baseline was 66.4% (97/146) by the Western criteria and 11.0% (16/146) by the Eastern criteria, and only low agreement was found between the Western and Eastern criteria (Kappa value = 0.028, p = 0.149). Patients who were sarcopenic by the Western criteria showed no significant difference in OS versus those who were not sarcopenic (p = 0.807). However, patients who were sarcopenic by the Eastern criteria showed a significant difference in OS versus those who were not sarcopenic in a univariate analysis (p = 0.008) and multivariate analysis after adjustment for AJCC stage (p = 0.014).
CONCLUSIONS: Our study demonstrates that different diagnostic criteria may result in different diagnoses and that sarcopenia is an important poor prognostic factor for pancreatic cancer when appropriate diagnostic criteria are selected.
Copyright © 2018 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Body compositions; Intra-abdominal fat; Pancreatic neoplasms; Sarcopenia; Tomography scanners; X-ray computed

Mesh:

Year:  2018        PMID: 29503056     DOI: 10.1016/j.clnu.2018.02.016

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  3 in total

1.  Prevalence of Low Muscle Mass in the Computed Tomography at the Third Lumbar Vertebra Level Depends on Chosen Cut-Off in 200 Hospitalised Patients-A Prospective Observational Trial.

Authors:  Arabella Fischer; Noemi Kiss; Valerie-Anna Rudas; Kristina Nieding; Cecilia Veraar; Isabel Timmermann; Konstantin Liebau; Maximilian Pesta; Timo Siebenrock; Martin Anwar; Ricarda Hahn; Anatol Hertwig; Jonas Brugger; Helmut Ringl; Dietmar Tamandl; Michael Hiesmayr
Journal:  Nutrients       Date:  2022-08-22       Impact factor: 6.706

2.  AWGS2019 vs EWGSOP2 for diagnosing sarcopenia to predict long-term prognosis in Chinese patients with gastric cancer after radical gastrectomy.

Authors:  Wen-Yi Wu; Jiao-Jiao Dong; Xin-Ce Huang; Zhe-Jing Chen; Xiao-Lei Chen; Qian-Tong Dong; Yong-Yu Bai
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

3.  Exploring definitions of radiological sarcopenia in cancer: a protocol for a scoping review.

Authors:  James Wei Wang; Matthew Williams
Journal:  BMJ Open       Date:  2021-07-02       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.